Investments
251Portfolio Exits
112About Qualifying Therapeutic Discovery Project
The Qualifying Therapeutic Discovery Project program was designed to promote medical research by providing tax credits and grants to small firms that show potential to produce new therapies, reduce long-term health care costs, or advance the goal of curing cancer within the next 30 years. The credit or grant covers up to 50 percent of the cost of qualifying biomedical research, up to a maximum credit of $5 million per firm and $1 billion overall, and is only available to firms with no more than 250 employees.
Latest Qualifying Therapeutic Discovery Project News
Aug 3, 2018
Xylos Corporation ("Xylos" or the "Company"), a leader in biocellulose technology for medical applications, announced recently that the Company was awarded a grant in the amount of $244,479 under the U.S. Xylos' application was focused on its innovative biomaterial solutions for the treatment, repair and replacement of human tissue. Among various eligibility guidelines, a QTDP applicant was required to demonstrate reasonable potential for its project to result in new therapies to treat areas of
Qualifying Therapeutic Discovery Project Investments
251 Investments
Qualifying Therapeutic Discovery Project has made 251 investments. Their latest investment was in Savara as part of their Grant - II on May 5, 2011.
Qualifying Therapeutic Discovery Project Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
5/16/2011 | Grant - II | Savara | $0.24M | Yes | ||
12/28/2010 | Grant - II | Kythera Biopharmaceuticals | $0.24M | No | ||
12/27/2010 | Grant - II | Groove Biopharma | $0.1M | No | ||
12/23/2010 | Grant | |||||
12/21/2010 | Grant |
Date | 5/16/2011 | 12/28/2010 | 12/27/2010 | 12/23/2010 | 12/21/2010 |
|---|---|---|---|---|---|
Round | Grant - II | Grant - II | Grant - II | Grant | Grant |
Company | Savara | Kythera Biopharmaceuticals | Groove Biopharma | ||
Amount | $0.24M | $0.24M | $0.1M | ||
New? | Yes | No | No | ||
Co-Investors | |||||
Sources |
Qualifying Therapeutic Discovery Project Portfolio Exits
112 Portfolio Exits
Qualifying Therapeutic Discovery Project has 112 portfolio exits. Their latest portfolio exit was Serina Therapeutics on August 30, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
8/30/2023 | Merger | 2 | |||
7/18/2023 | IPO | Public | 4 | ||
1/17/2023 | Acquired | 9 | |||
Date | 8/30/2023 | 7/18/2023 | 1/17/2023 | ||
|---|---|---|---|---|---|
Exit | Merger | IPO | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 2 | 4 | 9 |
Loading...